98%
921
2 minutes
20
Akt is a protein kinase that has been implicated in the progression of cancerous tumours. A number of covalent allosteric Akt inhibitors are known, and based on these scaffolds, a small library of novel potential covalent allosteric imidazopyridine-based inhibitors was designed. The envisaged compounds were synthesised, with click chemistry enabling a modular approach to a number of the target compounds. The binding modes, potencies and antiproliferative activities of these synthesised compounds were explored, thereby furthering the structure activity relationship knowledge of this class of Akt inhibitors. Three novel covalent inhibitors were identified, exhibiting moderate activity against Akt1 and various cancer cell lines, potentially paving the way for future covalent allosteric inhibitors with improved properties.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311865 | PMC |
http://dx.doi.org/10.1002/cmdc.202100776 | DOI Listing |
Bioorg Med Chem
September 2025
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, Egypt. Electronic address:
With the continued upsurge of antibiotic resistance and reduced susceptibility to almost all frontline antibiotics, there is a pressing need for the development of new, effective, and safe alternatives. In this study, a scaffold-hopping strategy was utilized to develop a novel class of penicillin-binding protein 2a (PBP2a) inhibitors, centered around a 4H-chromen-4-one core structure. These newly designed compounds demonstrated strong antibacterial efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant gram-positive pathogens.
View Article and Find Full Text PDFBioorg Chem
August 2025
Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Wuhan 430068, China; Hubei Key Laboratory of Industrial Microbiology, National "111" Center for Cellular Regulation and Molecular Pha
Upregulation of protein SUMOylation is associated with various diseases, and SUMOylation inhibitors are promising drug candidates. We performed the first virtual screening of SUMO E1 covalent allosteric inhibitors (CAIs) and identified two SUMO E1 CAIs with new scaffolds and covalent warheads. We further demonstrated that these new CAIs perturbed the SUMOylation pathway and protein SUMOylation.
View Article and Find Full Text PDFPharmaceuticals (Basel)
July 2025
Laboratory of Applied Chemistry and Environment (LCAE), Faculty of Science, University Mohammed Premier, Bd. Med VI B.P. 717, Oujda 60000, Morocco.
Oncogenic KRAS drives ~30% of solid tumours, yet the only approved G12C-specific drugs benefit ≈ 13% of KRAS-mutant patients, leaving a major clinical gap. We sought mutation-agnostic natural ligands from Ziziphus lotus, whose stereochemically rich phenolics may overcome this limitation by occupying the SI/II (Switch I/Switch II) groove and locking KRAS in its inactive state. Phytochemical mining yielded five recurrent phenolics, such as (+)-catechin, hyperin, astragalin, eriodictyol, and the prenylated benzoate amorfrutin A, benchmarked against the covalent inhibitor sotorasib.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
Schistosomes are parasitic flatworms that infect more than 200 million people globally. However, there is a shortage of molecular tools that enable the discovery of potential drug targets within schistosomes. Thus, praziquantel has remained the frontline treatment for schistosomiasis despite known liabilities.
View Article and Find Full Text PDFArch Toxicol
August 2025
Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Glycogen synthase kinase-3 (GSK-3) is a critical serine/threonine kinase that plays a central role in regulating various cellular processes. In the nervous system, GSK-3 is particularly implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Recent studies have demonstrated that GSK-3 modulates multiple pathological mechanisms through diverse signaling pathways, including PIK/Akt and Wnt/β-catenin.
View Article and Find Full Text PDF